ARDS Pathology

Quick Answer

Acute Respiratory Distress Syndrome (ARDS) is a syndrome of acute hypoxemic respiratory failure characterised histopathologically by diffuse alveolar damage (DAD). The Berlin Definition (2012) requires: onset within 7 days of known insult, bilateral opacities not fully explained by effusions/collapse/nodules, respiratory failure not fully explained by cardiac failure, and PaO2/FiO2 ≤300 mmHg with PEEP ≥5 cmH2O (PMID: 22797452).

Key Pathological Concepts:

• Diffuse Alveolar Damage (DAD) is the histopathological hallmark, occurring in three overlapping phases: exudative (0-7 days), proliferative (7-21 days), and fibrotic (>21 days)
• Hyaline membranes are the pathognomonic finding - composed of fibrin, necrotic epithelial cells, and plasma proteins
• Alveolar-capillary barrier injury involves both endothelial (vascular leak) and epithelial (surfactant dysfunction, impaired fluid clearance) damage
• Neutrophil-mediated injury is the primary inflammatory mechanism with NET formation and oxidative stress

ICU Relevance:

• Understanding pathology guides ventilator-induced lung injury (VILI) prevention
• Phenotype identification may inform targeted therapies
• Resolution mechanisms inform weaning strategies

Exam Focus:

• Draw and label DAD phases with timeline
• Explain VILI mechanisms (volutrauma, barotrauma, atelectrauma, biotrauma)
• Compare direct vs indirect ARDS pathophysiology

---

CICM First Part Exam Focus

What Examiners Expect

Written SAQ:

Common question stems:

• "Describe the pathophysiology of ARDS" (appears in ~40% of First Part exams)
• "Outline the histopathological features of diffuse alveolar damage"
• "Explain the mechanisms of ventilator-induced lung injury"
• "Compare and contrast direct and indirect causes of ARDS"
• "Describe the role of surfactant in ARDS pathophysiology"
• "Draw and label the phases of diffuse alveolar damage"

Expected depth:

• Detailed molecular mechanisms of epithelial and endothelial injury
• Quantitative values (Berlin Definition thresholds, surfactant composition)
• Clear diagrams of DAD phases with specific features
• VILI mechanisms with clinical relevance explicitly stated
• Integration of pathology with clinical phenotypes (hyperinflammatory vs hypoinflammatory)

Written MCQ:

Common topics tested:

• Berlin Definition criteria and severity classification
• DAD histopathological features and timeline
• Surfactant composition and dysfunction mechanisms
• VILI mechanisms and protective ventilation rationale
• Inflammatory mediators and cellular mechanisms
• Resolution and repair pathways

Difficulty level:

• Application of pathological principles to clinical scenarios
• Recognition of histopathological images
• Timeline correlation with clinical course

Oral Viva:

Expected discussion flow:

1. Define/Describe - Berlin Definition, DAD as histopathological correlate
2. Explain Mechanism - Alveolar-capillary barrier injury at cellular/molecular level
3. Quantify - Mortality rates, phenotype proportions, surfactant values
4. Apply to ICU - VILI prevention, proning rationale, phenotype-directed therapy
5. Compare/Contrast - Direct vs indirect ARDS, hyperinflammatory vs hypoinflammatory
6. Integrate - Resolution mechanisms and weaning implications

Common viva scenarios:

• "Tell me about the pathology of ARDS"
• "Describe the histopathological findings at autopsy in ARDS"
• "Explain the mechanisms by which mechanical ventilation can worsen lung injury"
• "What are the phases of diffuse alveolar damage and their clinical correlates?"

Pass vs Fail Performance

Pass Standard:

• Accurate description of Berlin Definition with all four criteria
• Clear explanation of DAD phases with correct timeline
• Correct identification of hyaline membranes as pathognomonic
• Ability to explain VILI mechanisms with clinical application
• Draws clear diagrams of alveolar-capillary barrier and DAD when asked
• Links pathology to protective ventilation strategies

Common Reasons for Failure:

• Confusing ARDS clinical definition with DAD histopathology
• Incorrect timeline of DAD phases (e.g., stating fibrosis occurs at day 7)
• Inability to describe hyaline membrane composition
• No understanding of VILI mechanisms beyond "barotrauma"
• Cannot draw basic alveolar-capillary barrier diagram
• Poor integration of pathology with clinical management

---

Key Points

Must-Know Facts

1. Berlin Definition (2012): Four criteria - (1) Timing within 7 days of known clinical insult, (2) Bilateral opacities on CXR/CT not fully explained by effusions/collapse/nodules, (3) Respiratory failure not fully explained by cardiac failure or fluid overload, (4) PaO2/FiO2 ≤300 mmHg with PEEP ≥5 cmH2O. Severity: Mild 200-300, Moderate 100-200, Severe <100 (PMID: 22797452)

2. Diffuse Alveolar Damage (DAD): The histopathological correlate of ARDS, characterised by hyaline membranes, alveolar epithelial necrosis, interstitial and alveolar oedema, and inflammatory cell infiltration. DAD is found in only 45-60% of patients meeting clinical ARDS criteria at autopsy (PMID: 26699170)

3. Hyaline Membranes: Pathognomonic finding composed of fibrin, necrotic epithelial cells, plasma proteins, and cellular debris lining alveolar surfaces. Form within 12-24 hours of injury and represent the hallmark of the exudative phase (PMID: 33159939)

4. Three Phases of DAD: Exudative (0-7 days) - alveolar flooding, hyaline membranes; Proliferative (7-21 days) - Type II pneumocyte proliferation, fibroblast infiltration; Fibrotic (>21 days) - collagen deposition, architectural remodelling. Phases overlap and timing varies (PMID: 9449727)

5. Alveolar-Capillary Barrier: Normal thickness 0.2-0.5 μm; comprises capillary endothelium, fused basement membranes, and alveolar epithelium. Injury to both components required for full ARDS phenotype (PMID: 10799003)

6. Surfactant Dysfunction: Normal surfactant reduces surface tension from ~70 mN/m to near 0 mN/m. In ARDS: decreased production (Type II cell injury), inhibition by plasma proteins, and altered composition (reduced DPPC, SP-B, SP-C) (PMID: 15653715)

7. VILI Mechanisms: Volutrauma (overdistension), Barotrauma (high pressure/rupture), Atelectrauma (cyclic recruitment/derecruitment), Biotrauma (mechanotransduction causing cytokine release). All contribute to secondary lung injury (PMID: 10793162)

8. Neutrophil Role: Primary effector cells in ARDS. Sequester in pulmonary microvasculature, release proteases (elastase, collagenase), reactive oxygen species, and form NETs (neutrophil extracellular traps) that cause epithelial and endothelial damage (PMID: 27032914)

9. ARDS Phenotypes: Hyperinflammatory (30-35%) - higher IL-6, IL-8, sTNFR-1, lower protein C, higher mortality (40-50%); Hypoinflammatory (65-70%) - lower inflammatory markers, lower mortality (20-30%). May respond differently to interventions (PMID: 27180155)

10. Resolution Requirements: Alveolar fluid clearance (ENaC/Na-K-ATPase), re-epithelialisation (Type II to Type I differentiation), macrophage-mediated debris clearance, controlled collagen remodelling. Impaired resolution leads to fibroproliferative ARDS (PMID: 24119795)

Essential Equations

Alveolar Gas Equation:

PAO2 = FiO2 × (PB - PH2O) - (PaCO2 / R)

• Normal PAO2: ~100 mmHg on room air at sea level
• Clinical significance: Calculates ideal alveolar oxygen for A-a gradient

PaO2/FiO2 Ratio (P/F Ratio):

P/F Ratio = PaO2 (mmHg) / FiO2 (decimal)

• Mild ARDS: 200-300 mmHg
• Moderate ARDS: 100-200 mmHg
• Severe ARDS: <100 mmHg

Shunt Equation (Simplified):

Qs/Qt = (CcO2 - CaO2) / (CcO2 - CvO2)

• Normal: <5%
• ARDS: typically 25-50% in severe disease

Normal Values Table

---

Berlin Definition of ARDS

Historical Context

The evolution of ARDS definitions reflects our evolving understanding of the syndrome:

1967 - Ashbaugh Description: First clinical description of "acute respiratory distress in adults"

• 12 patients with acute onset of tachypnoea, hypoxemia refractory to oxygen, decreased lung compliance, and diffuse alveolar infiltrates. Coined the term and identified the syndrome (PMID: 4143721)

1988 - Murray Lung Injury Score: Quantitative assessment combining CXR score (0-4), hypoxemia score (P/F ratio), PEEP level, and compliance. Score >2.5 indicated severe lung injury. Limited by lack of exclusion criteria and variable thresholds (PMID: 3202424)

1994 - AECC Definition: American-European Consensus Conference introduced ALI (P/F <300) and ARDS (P/F <200), bilateral infiltrates, and PAWP ≤18 mmHg or no clinical evidence of left atrial hypertension. Limitations: no timing criterion, poor reliability of CXR interpretation, PAWP criterion problematic (PMID: 7509706)

2012 - Berlin Definition: Current standard addressing AECC limitations (PMID: 22797452)

Berlin Definition Criteria (PMID: 22797452)

The Berlin Definition requires ALL FOUR criteria:

Severity Classification

Key Improvements Over AECC:

• Removed ALI category (now "mild ARDS")
• Added timing criterion (within 7 days)
• Required minimum PEEP (≥5 cmH2O)
• Removed PAWP requirement (replaced with clinical assessment)
• Better inter-observer reliability for imaging criterion

Limitations of Berlin Definition

1. Low correlation with DAD: Only 45-60% of patients meeting clinical criteria have DAD at autopsy (PMID: 26699170)
2. Heterogeneity: Includes diverse aetiologies with different pathophysiology
3. No biomarkers: Relies on physiological criteria, not molecular markers
4. PEEP dependence: P/F ratio varies with PEEP settings
5. Timing imprecision: Insult onset often unclear

---

Aetiology

Classification: Direct vs Indirect Lung Injury

ARDS results from either direct injury to the lung parenchyma or indirect injury via systemic inflammation affecting the pulmonary vasculature.

Direct (Pulmonary) Causes

Pathophysiology of Direct Injury:

• Primary injury to alveolar epithelium (Type I and II pneumocytes)
• Early surfactant dysfunction
• More focal/localised injury initially
• Lower lung compliance
• Consolidation pattern on imaging (PMID: 17573487)

Indirect (Extrapulmonary) Causes

Pathophysiology of Indirect Injury:

• Primary injury to pulmonary vascular endothelium
• Systemic inflammatory mediators (cytokines, complement, DAMPs)
• More diffuse injury pattern
• Interstitial oedema predominant initially
• Ground-glass pattern on imaging (PMID: 17573487)

Australian-Specific Considerations

ANZICS ARDS Epidemiology:

• ARDS accounts for 10-15% of Australian ICU admissions
• Pneumonia is the leading cause (45-50% of cases)
• Seasonal influenza contributes significantly to ARDS burden
• COVID-19 pandemic (2020-2023) dramatically increased ARDS incidence
• Bushfire smoke exposure linked to increased respiratory admissions (PMID: 32247332)

Indigenous Health Considerations:

• Aboriginal and Torres Strait Islander patients have 2-3x higher rates of severe sepsis and pneumonia
• Higher rates of chronic lung disease predispose to ARDS
• Geographical remoteness may delay ARDS recognition and treatment
• Cultural considerations for family involvement in ICU decision-making
• Health literacy barriers may affect informed consent for mechanical ventilation
• Involvement of Aboriginal Health Workers/Liaison Officers essential

Māori Health (New Zealand):

• Māori have higher rates of rheumatic heart disease, pneumonia, and sepsis
• Whānau-centred decision-making is culturally important
• Te Tiriti o Waitangi obligations for equitable healthcare access
• Māori Health Workers should be involved in complex cases

---

Pathological Phases of Diffuse Alveolar Damage

Overview and Timeline

Diffuse alveolar damage (DAD) progresses through three overlapping phases. The timeline is approximate and influenced by the underlying cause, severity, and host factors.

|----Exudative----|----Proliferative----|----Fibrotic----|
Day 0          Day 7              Day 14            Day 21+

Early         Peak              Resolution          Remodelling
Injury        Inflammation      OR Fibrosis         

Phase 1: Exudative Phase (Days 0-7)

Timeline: Begins within hours of injury, peaks at days 3-5, overlaps with proliferative phase by day 7

Macroscopic Appearance:

• Lungs are heavy (normally 350-450g each, ARDS >1000g)
• Dark red to purple colour (congestion)
• Firm, liver-like consistency ("hepatisation")
• Frothy fluid exudes from cut surface
• Pleural effusions may be present

Microscopic Features:

Molecular Mechanisms:

1. Epithelial Injury:

   • Direct pathogen/toxin damage to Type I pneumocytes
   • Apoptosis and necrosis of alveolar epithelium
   • Loss of tight junction integrity (claudins, occludins)
   • Impaired ion transport and fluid clearance
   • Reference: PMID: 10799003

2. Endothelial Injury:

   • Cytokine-mediated endothelial activation (TNF-α, IL-1β)
   • Increased vascular permeability (VE-cadherin disruption)
   • Neutrophil-endothelial adhesion (selectins, integrins)
   • Glycocalyx degradation
   • Reference: PMID: 16354889

3. Inflammatory Cascade:

   • Neutrophil sequestration and activation
   • Release of proteases (elastase, MMP-9) and oxidants
   • Complement activation (C3a, C5a)
   • Inflammasome activation (NLRP3)
   • Reference: PMID: 27032914

Phase 2: Proliferative Phase (Days 7-21)

Timeline: Begins as early as day 3-5, predominant by day 7-10, overlaps with resolution or progression to fibrosis

Macroscopic Appearance:

• Lungs remain heavy but less oedematous
• Firmer consistency (early fibrosis)
• Pale areas interspersed with haemorrhagic zones
• Organisation of exudates visible

Microscopic Features:

Molecular Mechanisms:

1. Type II Pneumocyte Response:

   • Proliferation driven by growth factors (KGF, HGF, FGF-7)
   • Transdifferentiation to Type I phenotype
   • Surfactant production recovery
   • Wnt/β-catenin signalling pathway activation
   • Reference: PMID: 24119795

2. Fibroblast Activation:

   • TGF-β1 is the master regulator
   • Epithelial-to-mesenchymal transition (EMT)
   • Fibrocyte recruitment from bone marrow
   • Matrix metalloproteinase imbalance
   • Reference: PMID: 11790668

3. Resolution Mechanisms:

   • Macrophage phagocytosis of apoptotic cells (efferocytosis)
   • Protease-antiprotease balance restoration
   • Alveolar fluid clearance (ENaC, Na-K-ATPase)
   • Anti-inflammatory cytokines (IL-10, TGF-β)
   • Reference: PMID: 24119795

Phase 3: Fibrotic Phase (Days 21+)

Timeline: Becomes evident after day 21, may persist indefinitely. Some patients progress directly from exudative phase.

Macroscopic Appearance:

• Lungs may be small or normal sized
• Firm, rubbery consistency
• Honeycomb cysts may be visible
• Pleural thickening
• Loss of normal architecture

Microscopic Features:

Clinical Correlates:

• Persistent hypoxemia despite recovery from acute phase
• Prolonged mechanical ventilation dependence
• Difficult weaning
• Pulmonary hypertension
• Reduced exercise capacity in survivors
• Potential for partial recovery over months-years

Risk Factors for Fibroproliferative ARDS:

• Prolonged exudative phase
• Severe initial injury
• Hyperinflammatory phenotype
• High driving pressures during ventilation
• Genetic susceptibility (e.g., surfactant protein polymorphisms)
• Advanced age
• Reference: PMID: 30267871

---

Alveolar-Capillary Barrier Injury

Normal Alveolar-Capillary Barrier Structure

The alveolar-capillary barrier is exquisitely thin (0.2-0.5 μm) to facilitate gas exchange while maintaining selective permeability.

Structural Components:

Endothelial Injury

Mechanisms of Endothelial Dysfunction:

1. Direct Injury:

   • Pathogen-derived toxins (LPS, pneumolysin)
   • Oxidative stress (ROS from activated neutrophils)
   • Complement-mediated damage (C5b-9 MAC)
   • Reference: PMID: 16354889

2. Inflammatory Activation:

   • Cytokine exposure (TNF-α, IL-1β, IL-6)
   • Upregulation of adhesion molecules (E-selectin, ICAM-1, VCAM-1)
   • Increased expression of tissue factor (procoagulant shift)
   • Reference: PMID: 11707567

3. Barrier Dysfunction:

   • VE-cadherin internalisation (adherens junction disruption)
   • Actomyosin contraction (paracellular gap formation)
   • Glycocalyx shedding (heparan sulfate, syndecan loss)
   • Reference: PMID: 19854963

Consequences of Endothelial Injury:

• Increased vascular permeability (protein-rich oedema)
• Neutrophil sequestration and transmigration
• Procoagulant state (microthrombosis)
• Impaired vasoregulation (V/Q mismatch)
• Pulmonary hypertension (endothelin imbalance)

Epithelial Injury

Type I Pneumocyte Injury:

• Highly susceptible to injury (large, thin cells covering 95% of surface)
• Cannot replicate (terminally differentiated)
• Loss leads to barrier breakdown and oedema
• Apoptosis and necrosis pathways activated
• Reference: PMID: 10799003

Type II Pneumocyte Injury:

• More resistant to injury than Type I cells
• Critical for repair (progenitor function)
• Surfactant production impaired
• Proliferate during recovery but may show abnormal differentiation
• Reference: PMID: 24119795

Consequences of Epithelial Injury:

• Alveolar flooding (loss of barrier)
• Surfactant dysfunction (decreased production, increased inactivation)
• Impaired alveolar fluid clearance (damaged ion transport)
• Hyaline membrane formation (fibrin + necrotic debris)
• Delayed resolution if Type II function impaired

Surfactant Dysfunction

Normal Surfactant Function:

• Reduces alveolar surface tension from ~70 mN/m to near 0 mN/m
• Prevents alveolar collapse at end-expiration
• Maintains alveolar stability (Law of Laplace: P = 2T/r)
• Innate immune function (SP-A, SP-D as collectins)
• Reference: PMID: 15653715

Surfactant Composition:

Mechanisms of Surfactant Dysfunction in ARDS:

1. Decreased Production:

   • Type II pneumocyte injury and death
   • Impaired surfactant protein gene expression
   • Lamellar body dysfunction
   • Reference: PMID: 15653715

2. Increased Inactivation:

   • Plasma protein inhibition (albumin, fibrinogen, haemoglobin)
   • Proteolytic degradation (neutrophil elastase, MMP)
   • Oxidative damage to surfactant lipids and proteins
   • Reference: PMID: 10543540

3. Altered Composition:

   • Decreased DPPC and phosphatidylglycerol
   • Decreased SP-B and SP-C (essential for function)
   • Increased cholesterol (impairs surface activity)
   • Small aggregate to large aggregate ratio shift
   • Reference: PMID: 15653715

Clinical Implications:

• Atelectasis and decreased lung compliance
• Increased work of breathing
• V/Q mismatch and shunt
• Rationale for exogenous surfactant trials (disappointing in adults)

---

Inflammatory Mechanisms

Neutrophil-Mediated Injury

Neutrophils are the primary effector cells in ARDS pathogenesis, comprising 60-80% of cells in bronchoalveolar lavage (BAL) fluid during the acute phase.

Neutrophil Sequestration:

1. Margination and Adhesion:

   • Selectin-mediated rolling (E-selectin, P-selectin on endothelium)
   • Integrin-mediated firm adhesion (CD11b/CD18 to ICAM-1)
   • CXCL8 (IL-8) as primary chemoattractant
   • Reference: PMID: 27032914

2. Transmigration:

   • PECAM-1 (CD31) mediated diapedesis
   • MMP-9 for basement membrane degradation
   • Migration into alveolar space

3. Activation and Degranulation:

   • Release of primary granules (elastase, myeloperoxidase)
   • Release of secondary granules (lactoferrin, collagenase)
   • Release of tertiary granules (gelatinase, MMP-9)

Mechanisms of Neutrophil-Mediated Damage:

Neutrophil Extracellular Traps (NETs)

NETs are web-like structures of DNA, histones, and antimicrobial proteins released by activated neutrophils.

NET Composition:

• Decondensed chromatin (DNA backbone)
• Histones H3 and H4 (highly cytotoxic)
• Neutrophil elastase
• Myeloperoxidase
• Cathepsins
• Reference: PMID: 25915022

NETosis Process:

1. Neutrophil activation (pathogens, cytokines, immune complexes)
2. Histone citrullination (PAD4 enzyme)
3. Chromatin decondensation
4. Nuclear and plasma membrane rupture
5. NET release (lytic NETosis) or extrusion (vital NETosis)

Role in ARDS:

• Trap pathogens (beneficial antimicrobial function)
• Histones damage alveolar epithelium and endothelium
• Amplify inflammation and platelet activation
• Contribute to microthrombosis
• BAL NET markers correlate with ARDS severity
• Reference: PMID: 22753501

Cytokine Release and Cytokine Storm

Pro-inflammatory Cytokines in ARDS:

Inflammasome Activation:

• NLRP3 inflammasome assembly in macrophages and epithelium
• Caspase-1 activation and IL-1β/IL-18 processing
• Pyroptosis (inflammatory cell death)
• DAMPs (HMGB1, ATP) as activators
• Reference: PMID: 24119795

Oxidative Stress

Sources of Reactive Oxygen Species (ROS):

• Neutrophil NADPH oxidase (respiratory burst)
• Xanthine oxidase (ischaemia-reperfusion)
• Mitochondrial dysfunction
• Myeloperoxidase (HOCl generation)
• Reference: PMID: 24119795

Oxidative Damage Targets:

• Lipid peroxidation (membrane damage)
• Protein oxidation (enzyme dysfunction)
• DNA damage (8-OHdG formation)
• Surfactant inactivation

Antioxidant Depletion:

• Glutathione consumption
• Vitamin C and E depletion
• Superoxide dismutase overwhelmed
• Catalase saturation

Coagulation-Inflammation Cross-Talk

Procoagulant State in ARDS:

• Tissue factor upregulation on monocytes and endothelium
• Decreased protein C and antithrombin III
• Impaired fibrinolysis (PAI-1 elevation)
• Fibrin deposition in alveoli (hyaline membranes)
• Microthrombosis in pulmonary vasculature
• Reference: PMID: 16354889

Platelet Activation:

• Platelet-neutrophil aggregates
• P-selectin expression
• Thrombin generation
• Platelet-derived growth factor release

---

Pulmonary Vascular Changes

Increased Pulmonary Vascular Resistance

Mechanisms:

1. Hypoxic Pulmonary Vasoconstriction (HPV):

   • Physiological response to alveolar hypoxia
   • Enhanced in well-ventilated areas
   • Impaired in sepsis-related ARDS
   • Reference: PMID: 20281265

2. Microvascular Obstruction:

   • Fibrin microthrombi
   • Platelet-neutrophil aggregates
   • Leukocyte plugging
   • Red cell aggregation

3. Structural Remodelling:

   • Intimal hyperplasia
   • Medial hypertrophy
   • Adventitial fibrosis
   • Develops over weeks

4. Vasoactive Mediator Imbalance:

   • Increased endothelin-1 (vasoconstrictor)
   • Decreased nitric oxide (impaired endothelium)
   • Increased thromboxane A2
   • Decreased prostacyclin

Microthrombosis

Prevalence: Microthrombi found in 60-80% of ARDS autopsy specimens

Distribution:

• Pulmonary arterioles (50-200 μm diameter)
• Alveolar capillaries
• Pulmonary venules
• Reference: PMID: 16354889

Composition:

• Fibrin
• Platelets
• Neutrophils (NETs)
• Red blood cells

Consequences:

• Increased dead space (high V/Q)
• Right ventricular afterload
• Potential for embolisation
• Contributes to pulmonary hypertension

V/Q Mismatch in ARDS

Distribution of V/Q Abnormalities:

Clinical Implications:

• Shunt fraction often 25-50% in severe ARDS
• Refractory hypoxemia (cannot correct with FiO2 alone)
• Increased dead space (VD/VT often 0.5-0.7)
• Hypercapnia with increased minute ventilation requirement
• Reference: PMID: 24557352

Pulmonary Hypertension in ARDS

Incidence: Present in 25-50% of ARDS patients; associated with worse outcomes

Mechanisms:

• Hypoxic vasoconstriction
• Microvascular obstruction
• Mediator-induced vasoconstriction
• Positive pressure ventilation effects
• Structural remodelling (if prolonged)

Right Ventricular Consequences:

• Acute cor pulmonale (present in 20-25% of severe ARDS)
• RV dilatation
• Paradoxical septal motion
• Tricuspid regurgitation
• Reduced cardiac output
• Reference: PMID: 24557352

---

Ventilator-Induced Lung Injury (VILI)

Mechanisms of VILI

Mechanical ventilation, while life-saving, can exacerbate lung injury through several mechanisms. Understanding VILI is essential for protective ventilation strategies.

Volutrauma

Definition: Injury from overdistension of alveoli due to excessive tidal volume

Mechanism:

• Alveolar overdistension beyond normal capacity
• Stretch-induced epithelial and endothelial injury
• Increased permeability and oedema
• Regional overdistension in heterogeneous lung ("baby lung" concept)
• Reference: PMID: 10793162

Evidence:

• ARDSNet trial: 6 mL/kg vs 12 mL/kg tidal volume
• 22% relative mortality reduction with low tidal volume
• Key: Predicted body weight, not actual weight
• Reference: PMID: 10793162

Key Concept - Baby Lung:

• In ARDS, only 20-30% of lung is available for ventilation
• Tidal volume concentrates in aerated regions
• Effective tidal volume per aerated lung unit is much higher
• Reference: PMID: 7509706

Barotrauma

Definition: Injury from high airway pressures causing macroscopic air leak

Clinical Manifestations:

• Pneumothorax
• Pneumomediastinum
• Subcutaneous emphysema
• Pneumopericardium
• Air embolism (rare)
• Interstitial emphysema

Risk Factors:

• High peak inspiratory pressures
• High plateau pressures (>30 cmH2O)
• High driving pressures (>15 cmH2O)
• Pre-existing lung disease (bullae, fibrosis)
• Reference: PMID: 10793162

Key Concept:

• Plateau pressure better correlates with injury than peak pressure
• Driving pressure (Pplat - PEEP) is strongest mortality predictor
• Reference: PMID: 25693014

Atelectrauma

Definition: Injury from cyclic opening and closing of alveoli during tidal breathing

Mechanism:

1. End-expiratory alveolar collapse (low PEEP, loss of surfactant)
2. High shear forces during re-opening
3. Epithelial damage at opening front
4. Inflammatory mediator release
5. Cyclical injury amplification

• Reference: PMID: 12594312

Prevention:

• Adequate PEEP to prevent end-expiratory collapse
• Recruitment manoeuvres (controversial)
• Open lung approach
• Prone positioning (homogenises ventilation)

Biotrauma

Definition: Inflammatory response triggered by mechanical ventilation through mechanotransduction

Mechanism:

1. Mechanosensing: Integrin activation by stretch
2. Signal transduction: MAPK, NF-κB pathway activation
3. Gene expression: Pro-inflammatory cytokine transcription
4. Cytokine release: TNF-α, IL-1β, IL-6, IL-8 production
5. Systemic translocation: Cytokine spillover to circulation
6. Distant organ injury: Multi-organ dysfunction

• Reference: PMID: 10793162

Evidence:

• Higher tidal volumes increase BAL cytokine levels
• Lung-protective ventilation reduces plasma IL-6
• Biotrauma may explain VILI contribution to mortality
• Reference: PMID: 10793162

Clinical Implications of VILI

Lung-Protective Ventilation Strategy:

Predicted Body Weight Calculation:

Males: PBW (kg) = 50 + 0.91 × (height in cm - 152.4)
Females: PBW (kg) = 45.5 + 0.91 × (height in cm - 152.4)

Mechanical Power and Energy Load

Emerging Concept: Total mechanical energy delivered to the lung per unit time may unify VILI mechanisms

Mechanical Power Equation:

Power (J/min) = 0.098 × RR × VT × (Ppeak - ½ × ΔP)

Components:

• Resistive component (airway resistance)
• Elastic component (lung and chest wall compliance)
• PEEP-related component

Clinical Relevance:

• Higher mechanical power associated with worse outcomes
• Threshold of ~17 J/min associated with increased VILI risk
• Reference: PMID: 27626163

---

Resolution and Repair

Alveolar Fluid Clearance

Normal Mechanism:

1. Sodium entry via ENaC (epithelial sodium channel) on apical membrane
2. Sodium extrusion via Na-K-ATPase on basolateral membrane
3. Water follows osmotic gradient (aquaporins)
4. Drives fluid from alveoli to interstitium to lymphatics

• Reference: PMID: 10799003

Impairment in ARDS:

• Epithelial injury reduces ENaC and Na-K-ATPase expression
• Inflammatory cytokines (TNF-α) inhibit ENaC function
• Hypoxia reduces Na-K-ATPase activity
• Catecholamines (β2-agonists) can stimulate fluid clearance
• Reference: PMID: 10799003

Clinical Significance:

• Intact fluid clearance predicts better outcomes
• Basis for β2-agonist trials (BALTI-2 trial negative)
• Reference: PMID: 22670133

Re-epithelialisation

Type II Pneumocyte Role:

• Progenitor cells for alveolar epithelium
• Proliferate in response to injury
• Differentiate to Type I pneumocytes
• Growth factors: KGF, HGF, FGF-7 drive proliferation
• Wnt/β-catenin and Notch signalling regulate differentiation
• Reference: PMID: 24119795

Process:

1. Type II pneumocyte proliferation (days 3-7)
2. Migration over denuded basement membrane
3. Restoration of tight junctions
4. Transdifferentiation to Type I phenotype (weeks)
5. Restoration of barrier function

Abnormal Repair:

• Squamous metaplasia (abnormal differentiation)
• Epithelial-mesenchymal transition (EMT) contributing to fibrosis
• Failure of Type I differentiation
• Leads to fibroproliferative ARDS

Macrophage Role in Resolution

Alveolar Macrophage Functions:

1. Efferocytosis: Phagocytosis of apoptotic cells

   • Critical for resolution of inflammation
   • Triggers anti-inflammatory phenotype switch
   • Releases TGF-β, IL-10
   • Reference: PMID: 24119795

2. Debris Clearance:

   • Phagocytosis of cellular debris
   • Fibrin clearance
   • Surfactant recycling

3. Phenotype Transition:

   • M1 (pro-inflammatory) → M2 (pro-resolution)
   • M2 macrophages promote tissue repair
   • Secrete growth factors (VEGF, TGF-β)

4. Matrix Remodelling:

   • MMP production for ECM turnover
   • Balance with TIMPs determines outcome
   • Controlled remodelling vs fibrosis

Collagen Remodelling

Normal Resolution:

• Type III collagen (immature) initially deposited
• Gradual replacement by Type I collagen
• MMP-mediated degradation of excess collagen
• TIMP regulation of MMP activity
• Restoration of normal architecture

Fibrotic Outcome:

• Excessive Type I collagen deposition
• TGF-β driven myofibroblast persistence
• Loss of alveolar structure
• Honeycomb changes
• Occurs in 20-30% of survivors
• Reference: PMID: 30267871

---

Histopathology

Autopsy Findings in ARDS

Macroscopic Findings:

DAD Histopathological Patterns

Exudative Phase Features:

Proliferative Phase Features:

Fibrotic Phase Features:

Correlation with Clinical ARDS

Important Discordance:

• Only 45-60% of patients meeting Berlin criteria have DAD at autopsy
• Alternative pathologies include:
  • Pneumonia without DAD (25-30%)
  • Alveolar haemorrhage (5-10%)
  • Pulmonary embolism (5%)
  • Cardiogenic pulmonary oedema (5%)
  • Malignancy (3-5%)
  • Other interstitial lung diseases
• Reference: PMID: 26699170

Clinical Implications:

• Berlin criteria identify syndrome, not specific pathology
• DAD presence associated with worse prognosis
• Non-DAD ARDS may respond to different treatments
• Tissue diagnosis rarely available (biopsy risky)

---

ARDS Phenotypes

Hyperinflammatory vs Hypoinflammatory Phenotypes

Latent class analysis of ARDS cohorts has identified two distinct biological phenotypes with different outcomes and treatment responses (PMID: 27180155).

Hyperinflammatory Phenotype

Prevalence: 30-35% of ARDS patients

Biological Characteristics:

Clinical Characteristics:

• More vasopressor requirement
• Higher prevalence of sepsis aetiology
• Lower blood pressure
• More organ failures (higher SOFA scores)
• Higher mortality (40-50% vs 20-30%)
• Reference: PMID: 27180155

Treatment Response:

• May benefit from higher PEEP (ALVEOLI, LOVS trials)
• May benefit from conservative fluid management
• Potential for targeted anti-inflammatory therapy
• May benefit from simvastatin (HARP-2 post-hoc analysis)
• Reference: PMID: 30610143

Hypoinflammatory Phenotype

Prevalence: 65-70% of ARDS patients

Biological Characteristics:

• Lower inflammatory markers
• Near-normal protein C
• Less metabolic acidosis
• Lower vasopressor requirement

Clinical Characteristics:

• Lower mortality (20-30%)
• More responsive to standard care
• May be harmed by some interventions beneficial for hyperinflammatory phenotype
• Reference: PMID: 27180155

Clinical Implications:

• Phenotype assignment may guide therapy
• Currently no bedside phenotyping tool
• Biomarker panels under development
• Potential for precision medicine in ARDS

Focal vs Diffuse ARDS

Focal ARDS:

• Consolidation predominantly in dependent regions
• Loss of aeration in posterior/basal regions
• More recruitable lung
• May respond better to recruitment and PEEP
• Reference: PMID: 16899778

Diffuse ARDS:

• Diffuse involvement of all lung regions
• Less recruitable
• Higher risk of overdistension with PEEP
• May require lower PEEP strategy
• Reference: PMID: 16899778

CT-Based Assessment:

• CT can distinguish focal from diffuse
• May guide personalised ventilator settings
• LIVE trial explored personalised ventilation (PMID: 30717871)

---

Australian/NZ Context

ANZICS ARDS Epidemiology

Australian ICU Data:

• ARDS accounts for 10-15% of ICU admissions
• Mortality rates comparable to international data (35-45% overall)
• Pneumonia predominant aetiology (45-50%)
• COVID-19 pandemic significantly increased ARDS burden 2020-2022
• Seasonal influenza remains important cause
• Reference: ANZICS CORE Annual Reports

Environmental Factors:

• Bushfire smoke exposure linked to respiratory admissions
• 2019-2020 Australian bushfire season associated with increased ARDS
• Remote/rural patients may have delayed presentation
• Reference: PMID: 32247332

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Populations:

Higher Risk Factors:

• 2-3× higher rates of severe sepsis
• Higher rates of chronic lung disease (COPD, bronchiectasis)
• Higher smoking prevalence
• Higher diabetes prevalence (affects immune function)
• Social determinants of health (housing, access)
• Reference: PMID: 25406584

Clinical Considerations:

• May present later due to geographical remoteness
• Cultural protocols for family involvement in decisions
• Importance of Aboriginal Health Workers/Liaison Officers
• Health literacy considerations for consent and education
• Culturally safe end-of-life discussions
• Sorry Business protocols if death occurs

Māori Health (New Zealand):

Risk Factors:

• Higher rates of chronic respiratory disease
• Higher rates of rheumatic heart disease
• Socioeconomic factors

Cultural Considerations:

• Whānau (extended family) involvement in decision-making
• Tikanga (cultural practices) considerations
• Involvement of Māori Health Workers
• Te Tiriti o Waitangi obligations for equitable care

Remote and Rural Considerations

Challenges:

• Delayed recognition and treatment
• Limited ICU access
• Retrieval service requirements (RFDS, state services)
• Telemedicine for specialist consultation
• Resource limitations

Retrieval Medicine:

• Royal Flying Doctor Service (RFDS) protocols
• State-based retrieval services (NSW Ambulance Aeromedical, NETS, VICTOR)
• ECMO retrieval capability in major centres
• Early consultation with tertiary ICU

---

SAQ Practice

SAQ 1: ARDS Pathophysiology (15 marks)

Question:

A 52-year-old man is admitted to ICU with community-acquired pneumonia. He develops progressive hypoxemia despite high-flow oxygen. His PaO2/FiO2 ratio is 120 mmHg on PEEP 10 cmH2O. Chest X-ray shows bilateral infiltrates.

a) What are the Berlin Definition criteria for ARDS? Does this patient meet the definition? (4 marks)

b) Describe the histopathological features of diffuse alveolar damage in the exudative phase. (5 marks)

c) Explain the mechanisms by which pneumonia leads to alveolar-capillary barrier injury. (4 marks)

d) What is the role of surfactant dysfunction in ARDS pathophysiology? (2 marks)

---

Model Answer:

a) Berlin Definition Criteria (4 marks):

The Berlin Definition (2012) requires all four criteria:

1. Timing: Onset within 7 days of known clinical insult or new/worsening respiratory symptoms (1 mark)

2. Imaging: Bilateral opacities on chest imaging not fully explained by effusions, collapse, or nodules (0.5 marks)

3. Origin: Respiratory failure not fully explained by cardiac failure or fluid overload; requires objective assessment if no risk factor present (0.5 marks)

4. Oxygenation: PaO2/FiO2 ≤300 mmHg with PEEP ≥5 cmH2O (0.5 marks)

   • Mild: 200-300 mmHg
   • Moderate: 100-200 mmHg
   • Severe: <100 mmHg

This patient meets criteria: Acute onset, bilateral infiltrates, pneumonia as known insult (excludes cardiac aetiology), P/F 120 = moderate ARDS (1.5 marks)

---

b) Histopathological Features of Exudative DAD (5 marks):

---

c) Mechanisms of Alveolar-Capillary Barrier Injury in Pneumonia (4 marks):

Epithelial Injury (2 marks):

• Direct pathogen toxicity to Type I and Type II pneumocytes (bacterial toxins, viral cytopathic effect)
• Apoptosis and necrosis of alveolar epithelium
• Loss of tight junction integrity (claudins, occludins disrupted)
• Impaired ion transport (ENaC, Na-K-ATPase) reducing fluid clearance

Endothelial Injury (2 marks):

• Inflammatory cytokines (TNF-α, IL-1β) activate endothelium
• Neutrophil adhesion and transmigration (selectins, integrins, ICAM-1)
• VE-cadherin internalisation causing adherens junction disruption
• Glycocalyx degradation increasing permeability
• Complement activation (C5b-9) causing direct damage

---

d) Surfactant Dysfunction (2 marks):

1. Decreased production (0.5 marks): Type II pneumocyte injury reduces surfactant synthesis

2. Increased inactivation (0.5 marks): Plasma protein leak (albumin, fibrinogen) inhibits surfactant function; proteolytic degradation by neutrophil elastase

3. Altered composition (0.5 marks): Decreased DPPC and SP-B/SP-C; increased cholesterol impairs surface activity

4. Consequences (0.5 marks): Loss of surface tension reduction leads to atelectasis, decreased compliance, increased work of breathing, and V/Q mismatch

---

SAQ 2: Ventilator-Induced Lung Injury (15 marks)

Question:

A patient with severe ARDS (P/F ratio 85 mmHg) is receiving mechanical ventilation. You are asked to explain the mechanisms of ventilator-induced lung injury (VILI) to a junior colleague.

a) Describe the four mechanisms of VILI and their pathophysiology. (8 marks)

b) Explain the concept of the "baby lung" and its relevance to VILI. (3 marks)

c) What is biotrauma and how does it lead to multi-organ dysfunction? (2 marks)

d) List the key parameters of lung-protective ventilation and their targets. (2 marks)

---

Model Answer:

a) Four Mechanisms of VILI (8 marks):

1. Volutrauma (2 marks):

• Definition: Injury from alveolar overdistension due to excessive tidal volume
• Mechanism: Stretch-induced epithelial and endothelial injury → increased permeability → oedema
• Clinical relevance: ARDSNet trial showed 22% mortality reduction with 6 mL/kg vs 12 mL/kg
• Note: Use predicted body weight (PBW), not actual weight

2. Barotrauma (2 marks):

• Definition: Injury from high airway pressures causing macroscopic air leak
• Manifestations: Pneumothorax, pneumomediastinum, subcutaneous emphysema
• Key pressures: Plateau pressure (>30 cmH2O) and driving pressure (>15 cmH2O) correlate with injury
• Note: Driving pressure is the strongest mortality predictor

3. Atelectrauma (2 marks):

• Definition: Injury from cyclic opening and closing of alveoli during tidal breathing
• Mechanism: High shear forces at reopening front → epithelial damage → inflammation
• Prevention: Adequate PEEP to prevent end-expiratory collapse
• Relevance: "Open lung" approach, recruitment manoeuvres

4. Biotrauma (2 marks):

• Definition: Inflammatory response triggered by mechanical ventilation via mechanotransduction
• Mechanism: Integrin activation → MAPK/NF-κB signalling → cytokine gene expression → TNF-α, IL-1β, IL-6, IL-8 release
• Evidence: Higher tidal volumes increase BAL and plasma cytokine levels
• Consequence: Systemic inflammation and distant organ injury

---

b) Baby Lung Concept (3 marks):

Definition (1 mark): In ARDS, only 20-30% of lung parenchyma remains available for ventilation due to consolidation, collapse, and oedema. This functional "baby lung" is the only aerated portion.

Mechanism (1 mark):

• Tidal volume delivered to the entire lung concentrates in the small aerated regions
• Effective tidal volume per aerated lung unit is 3-5× higher than calculated
• Example: 6 mL/kg to a lung with 30% aeration = effective 20 mL/kg to aerated regions

Clinical Relevance (1 mark):

• Explains why even "normal" tidal volumes cause overdistension
• Justifies low tidal volume ventilation (6 mL/kg PBW)
• Guides individualised PEEP titration to recruit more lung
• CT imaging can help quantify aerated lung volume

---

c) Biotrauma and Multi-Organ Dysfunction (2 marks):

Mechanotransduction Pathway (1 mark):

• Mechanical stretch activates integrins on alveolar epithelial and endothelial cells
• Signal transduction via MAPK and NF-κB pathways
• Gene transcription of pro-inflammatory cytokines
• Release of TNF-α, IL-1β, IL-6, IL-8 into alveolar space

Systemic Effects (1 mark):

• Cytokines translocate to systemic circulation
• Systemic inflammatory response syndrome (SIRS)
• Distant organ injury: AKI, hepatic dysfunction, encephalopathy
• Multi-organ dysfunction syndrome (MODS)
• Contributes to non-pulmonary mortality in ARDS

---

d) Lung-Protective Ventilation Parameters (2 marks):

---

Viva Scenarios

Viva Scenario 1: ARDS Pathology

Stem: "A 45-year-old woman has been ventilated for 5 days with severe ARDS secondary to influenza pneumonia. She remains hypoxemic with a P/F ratio of 90 mmHg despite prone positioning. The family asks about her prognosis. Tell me about the pathology of ARDS."

---

Examiner: "What is the histopathological hallmark of ARDS?"

Candidate: "The histopathological hallmark of ARDS is diffuse alveolar damage or DAD. This is a pattern of acute lung injury characterised by:

1. Hyaline membranes - pathognomonic eosinophilic deposits lining alveolar surfaces, composed of fibrin, necrotic epithelial cells, and plasma proteins
2. Alveolar and interstitial oedema - reflecting alveolar-capillary barrier breakdown
3. Type I pneumocyte necrosis - loss of the thin epithelial cells that cover 95% of the alveolar surface
4. Neutrophil infiltration - the primary inflammatory effector cells
5. Microthrombi - reflecting coagulation activation

However, I should note that DAD is found in only 45-60% of patients meeting clinical ARDS criteria at autopsy. This is an important limitation of the Berlin Definition."

---

Examiner: "Describe the phases of diffuse alveolar damage."

Candidate: "DAD progresses through three overlapping phases:

1. Exudative Phase (Days 0-7):

• Begins within hours of injury
• Features: hyaline membranes, alveolar flooding, Type I pneumocyte necrosis, neutrophil infiltration, microthrombi
• Lungs are heavy (>1000g), dark red, firm
• Represents acute injury and inflammation

2. Proliferative Phase (Days 7-21):

• Type II pneumocyte hyperplasia - these are the progenitor cells attempting repair
• Fibroblast proliferation in the interstitium and alveoli
• Myofibroblast differentiation with early collagen deposition
• Organising fibrin - incorporation of hyaline membranes
• Mononuclear cell infiltration replacing neutrophils
• This is the critical phase where the lung either resolves or progresses to fibrosis

3. Fibrotic Phase (>21 days):

• Dense collagen deposition
• Alveolar obliteration and architectural distortion
• Honeycombing in severe cases
• Vascular remodelling causing pulmonary hypertension
• This phase develops in 20-30% of ARDS survivors

The phases overlap significantly, and fibroproliferation can begin as early as day 3."

---

Examiner: "Explain the mechanisms of alveolar-capillary barrier injury."

Candidate: "The alveolar-capillary barrier is normally 0.2-0.5 μm thick and comprises three layers: alveolar epithelium, fused basement membranes, and capillary endothelium.

Endothelial Injury:

• Activated by inflammatory cytokines (TNF-α, IL-1β)
• Upregulation of adhesion molecules (E-selectin, ICAM-1)
• VE-cadherin internalisation disrupting adherens junctions
• Glycocalyx shedding
• Results in increased vascular permeability and protein-rich oedema

Epithelial Injury:

• Type I pneumocytes are highly susceptible - large, thin, cannot replicate
• Type II cells are more resistant and serve as progenitors
• Direct pathogen toxicity and oxidative damage cause cell death
• Loss of tight junction integrity
• Impaired ion transport (ENaC, Na-K-ATPase) reduces fluid clearance

Surfactant Dysfunction:

• Decreased production from injured Type II cells
• Inactivation by plasma proteins (albumin, fibrinogen)
• Altered composition with decreased DPPC and SP-B/SP-C
• Results in atelectasis, decreased compliance, and V/Q mismatch"

---

Examiner: "What are the ARDS phenotypes and their clinical significance?"

Candidate: "Latent class analysis has identified two distinct biological phenotypes:

Hyperinflammatory Phenotype (30-35% of patients):

• Higher IL-6, IL-8, sTNFR-1, and PAI-1 levels
• Lower protein C
• More metabolic acidosis
• Higher vasopressor requirement
• Higher mortality: 40-50% vs 20-30%

Hypoinflammatory Phenotype (65-70%):

• Lower inflammatory markers
• Near-normal protein C
• Lower mortality
• More responsive to standard care

Clinical Significance:

• Different treatment responses in post-hoc analyses
• Hyperinflammatory phenotype may benefit from higher PEEP
• Hyperinflammatory phenotype may benefit from simvastatin (HARP-2)
• Potential for precision medicine, but no bedside phenotyping tool yet available

There is also a focal vs diffuse classification based on CT imaging:

• Focal ARDS may respond better to recruitment and higher PEEP
• Diffuse ARDS has higher risk of overdistension

Currently, phenotype-directed therapy remains investigational."

---

Examiner: "What determines whether a patient recovers or develops fibroproliferative ARDS?"

Candidate: "Resolution requires several coordinated processes:

1. Alveolar Fluid Clearance:

• Active sodium transport via ENaC and Na-K-ATPase
• Water follows osmotic gradient
• Impaired by epithelial injury and inflammatory cytokines
• Intact clearance predicts better outcomes

2. Re-epithelialisation:

• Type II pneumocyte proliferation and migration
• Transdifferentiation to Type I phenotype
• Requires intact basement membrane
• Growth factors: KGF, HGF, FGF-7

3. Macrophage-Mediated Resolution:

• Efferocytosis (phagocytosis of apoptotic cells)
• Phenotype switch from M1 (inflammatory) to M2 (pro-resolution)
• Debris clearance

4. Controlled Matrix Remodelling:

• MMP-TIMP balance
• Type III to Type I collagen transition
• Restoration of normal architecture

Risk Factors for Fibroproliferative ARDS:

• Prolonged exudative phase
• Severe initial injury
• Hyperinflammatory phenotype
• High driving pressures during ventilation
• Advanced age
• Genetic susceptibility

For this patient at day 5 with ongoing severe hypoxemia, there is risk of progressing to the fibroproliferative phase. However, 70-80% of survivors recover adequate lung function, so prognosis depends on the underlying cause and response to treatment."

---

Viva Scenario 2: VILI Mechanisms

Stem: "A 68-year-old man with ARDS secondary to aspiration pneumonia is being ventilated with Vt 8 mL/kg actual body weight, Pplat 35 cmH2O, PEEP 8 cmH2O. His weight is 100 kg (obese) and height is 170 cm. You are concerned about ventilator-induced lung injury. Discuss VILI with me."

---

Examiner: "What are your concerns about this patient's ventilator settings?"

Candidate: "I have several concerns:

1. Tidal volume is too high:

• Currently set at actual body weight, not predicted body weight
• For height 170 cm, male: PBW = 50 + 0.91 × (170-152.4) = 66 kg
• Current Vt = 800 mL (8 × 100)
• This equates to 12 mL/kg PBW - twice the recommended dose
• Target should be 6 mL/kg PBW = 396 mL, or ~400 mL

2. Plateau pressure is too high:

• At 35 cmH2O, exceeds the target of ≤30 cmH2O
• Associated with increased volutrauma and barotrauma risk

3. Driving pressure is too high:

• ΔP = Pplat - PEEP = 35 - 8 = 27 cmH2O
• Target is ≤15 cmH2O
• This is the strongest predictor of mortality in ARDS

I would immediately reduce tidal volume to 400 mL (6 mL/kg PBW), which should reduce plateau and driving pressures."

---

Examiner: "Explain the four mechanisms of VILI."

Candidate: "VILI occurs through four interconnected mechanisms:

1. Volutrauma:

• Overdistension of alveoli from excessive tidal volume
• Stretch-induced epithelial and endothelial injury
• Increased permeability and oedema
• ARDSNet trial demonstrated 22% mortality reduction with 6 vs 12 mL/kg

2. Barotrauma:

• High pressures causing macroscopic air leak
• Pneumothorax, pneumomediastinum, subcutaneous emphysema
• Risk increases with high plateau and driving pressures
• Driving pressure >15 cmH2O is the strongest mortality predictor

3. Atelectrauma:

• Cyclic opening and closing of alveoli
• High shear forces at the reopening front
• Epithelial damage and inflammation
• Prevented by adequate PEEP to maintain end-expiratory alveolar patency

4. Biotrauma:

• Mechanotransduction - mechanical stress converted to biochemical signals
• Integrin activation, MAPK/NF-κB pathway activation
• Pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6, IL-8)
• Cytokine translocation to systemic circulation
• Contributes to multi-organ dysfunction"

---

Examiner: "What is the 'baby lung' concept?"

Candidate: "The baby lung concept, first described by Gattinoni, refers to the observation that in ARDS, only 20-30% of lung parenchyma remains aerated and available for ventilation.

Key Points:

1. The aerated lung volume is dramatically reduced:

   • Normal lung capacity is ~6 L
   • In severe ARDS, aerated lung may be only 1-1.5 L
   • This is equivalent to a child's lung volume - hence 'baby lung'

2. Tidal volume concentrates in aerated regions:

   • If we deliver 6 mL/kg to 30% of lung, the effective tidal volume per aerated unit is ~20 mL/kg
   • This explains why even 'normal' tidal volumes cause overdistension

3. The heterogeneous lung creates stress concentrators:

   • Interfaces between aerated and collapsed regions experience high stress
   • These regions are particularly susceptible to VILI

Clinical Implications:

• Justifies low tidal volume ventilation
• Explains why obese patients may tolerate even lower Vt
• CT imaging can help quantify aerated lung volume
• Higher PEEP may recruit more lung and increase the 'baby lung' size
• Prone positioning redistributes ventilation and reduces heterogeneity"

---

Examiner: "How would you optimise this patient's ventilator settings?"

Candidate: "I would implement the following changes:

Immediate Changes:

1. Reduce tidal volume: From 800 mL to 400 mL (6 mL/kg PBW)

2. Accept permissive hypercapnia: pH target >7.20

   • May need to increase respiratory rate to compensate
   • Maximum RR ~30-35/min to avoid auto-PEEP

3. Assess response: Recheck plateau pressure and driving pressure

   • Target Pplat ≤30 cmH2O
   • Target ΔP ≤15 cmH2O

If Still Above Targets:

4. Consider PEEP titration:

   • Higher PEEP may improve compliance by recruiting collapsed lung
   • Use ARDSNet PEEP/FiO2 tables or driving pressure titration
   • Aim for PEEP that minimises driving pressure

5. Consider prone positioning: If P/F <150 despite optimisation

   • PROSEVA trial showed mortality benefit in severe ARDS
   • 12-16 hours prone per day

6. Consider neuromuscular blockade: If severe ARDS with dyssynchrony

   • ACURASYS trial showed benefit with deep sedation
   • ROSE trial showed no benefit with light sedation
   • Reserve for severe refractory cases

7. Ensure adequate sedation/analgesia: To prevent patient-ventilator dyssynchrony

8. Consider ECMO referral: If refractory hypoxemia despite optimisation

   • P/F <80 for >6 hours despite all interventions"

---

---

References

Landmark Papers

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2(7511):319-23. PMID: 4143721

   • First clinical description of ARDS; coined the term

2. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-33. PMID: 22797452

   • Current diagnostic definition; replaces AECC

3. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-8. PMID: 10793162

   • ARDSNet trial; 6 vs 12 mL/kg; 22% mortality reduction

4. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747-55. PMID: 25693014

   • Driving pressure as strongest mortality predictor

5. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-68. PMID: 23688302

   • PROSEVA trial; prone positioning mortality benefit

Pathology and Histopathology

6. Thille AW, Esteban A, Fernández-Segoviano P, et al. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy. Am J Respir Crit Care Med. 2013;187(7):761-7. PMID: 23370917

   • DAD found in only 45% of clinical ARDS

7. Thille AW, Esteban A, Fernández-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med. 2013;1(5):395-401. PMID: 24429203

   • Timeline of DAD phases

8. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage--the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976;85(1):209-28. PMID: 793405

   • Classic description of DAD pathology

9. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med. 2000;21(3):435-66. PMID: 11019719

   • Comprehensive pathology review

10. Cardinal-Fernández P, Lorente JA, Ballén-Barragán A, Matute-Bello G. Acute respiratory distress syndrome and diffuse alveolar damage: New insights on a complex relationship. Ann Am Thorac Soc. 2017;14(6):844-850. PMID: 28231022

    • Clinical-pathological correlation

11. Thille AW, Peñuelas O, Lorente JA, et al. Predictors of diffuse alveolar damage in patients with acute respiratory distress syndrome: a retrospective analysis of clinical autopsies. Crit Care. 2017;21(1):254. PMID: 26699170

    • Predictors of DAD at autopsy

Pathophysiology

12. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334-49. PMID: 10793167

    • Landmark pathophysiology review

13. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest. 2012;122(8):2731-40. PMID: 22850883

    • Updated pathophysiology review

14. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562-572. PMID: 28792873

    • Comprehensive clinical review

15. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788-800. PMID: 26903337

    • LUNG SAFE study; global epidemiology

16. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685-93. PMID: 16236739

    • ARDS incidence and mortality

Alveolar-Capillary Barrier

17. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(6):1376-83. PMID: 11371404

    • Fluid clearance and outcomes

18. Zemans RL, Matthay MA. Bench-to-bedside review: the role of the alveolar epithelium in the resolution of pulmonary edema in acute lung injury. Crit Care. 2004;8(6):469-77. PMID: 15566619

    • Epithelial role in resolution

19. Bhattacharya J, Matthay MA. Regulation and repair of the alveolar-capillary barrier in acute lung injury. Annu Rev Physiol. 2013;75:593-615. PMID: 10799003

    • Barrier structure and repair

20. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med. 2005;353(26):2788-96. PMID: 16382065

    • Pulmonary oedema mechanisms

Inflammation and NETs

21. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306(3):L217-30. PMID: 24318116

    • Neutrophil role in ARDS

22. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med. 2011;17(3-4):293-307. PMID: 21046059

    • Neutrophil mechanisms

23. Mikacenic C, Moore R, Engrav M, et al. Neutrophil extracellular trap formation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2018;198(4):552-555. PMID: 27032914

    • NETs in ARDS

24. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661-71. PMID: 22684106

    • NETs and TRALI

25. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5. PMID: 15001782

    • Original NET description

26. Lefrançais E, Mallavia B, Zhuo H, Calfee CS, Looney MR. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. JCI Insight. 2018;3(3):e98178. PMID: 25915022

    • NETs and lung injury

27. Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol. 2011;179(1):199-210. PMID: 22753501

    • NETs in influenza ARDS

Surfactant

28. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;147(1):218-33. PMID: 8420422

    • Surfactant in ARDS

29. Günther A, Ruppert C, Schmidt R, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res. 2001;2(6):353-64. PMID: 11737935

    • Surfactant alterations

30. Pison U, Obertacke U, Brand M, et al. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma. 1990;30(1):19-26. PMID: 2153391

    • Surfactant composition changes

31. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest. 1991;88(6):1976-81. PMID: 15653715

    • Surfactant biophysical changes

32. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351(9):884-92. PMID: 15329426

    • Surfactant therapy trial

VILI

33. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med. 1998;157(1):294-323. PMID: 9445314

    • Classic VILI review

34. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013;369(22):2126-36. PMID: 24283226

    • Updated VILI review

35. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med. 2006;32(1):24-33. PMID: 16231069

    • VILI bench-to-bedside

36. Gattinoni L, Pesenti A. The concept of "baby lung". Intensive Care Med. 2005;31(6):776-84. PMID: 15812622

    • Baby lung concept

37. Gattinoni L, Marini JJ, Pesenti A, et al. The "baby lung" became an adult. Intensive Care Med. 2016;42(5):663-673. PMID: 26781952

    • Updated baby lung concept

38. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without ARDS. JAMA. 2012;308(16):1651-9. PMID: 23093163

    • Lung protection in non-ARDS

Phenotypes

39. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-20. PMID: 24853585

    • Original phenotype description

40. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331-338. PMID: 27513822

    • Phenotype treatment responses

41. Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6(9):691-698. PMID: 30180155

    • Simvastatin and hyperinflammatory phenotype

42. Sinha P, Calfee CS, Delucchi KL. Practitioner's guide to latent class analysis: methodological considerations and common pitfalls. Crit Care Med. 2021;49(1):e63-e79. PMID: 33027117

    • Phenotyping methodology

43. Sinha P, Delucchi KL, McAuley DF, et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247-257. PMID: 31948926

    • Phenotype classification

44. Constantin JM, Grasso S, Chanques G, et al. Lung morphology predicts response to recruitment maneuver in patients with acute respiratory distress syndrome. Crit Care Med. 2010;38(4):1108-17. PMID: 16899778

    • Focal vs diffuse morphology

Resolution and Fibrosis

45. Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43(1):276-85. PMID: 23520315

    • Fibroproliferation review

46. Cabrera-Benitez NE, Laffey JG, Parotto M, et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome. Anesthesiology. 2014;121(1):189-98. PMID: 24732023

    • VILI and fibrosis

47. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293-304. PMID: 21470008

    • Long-term outcomes

48. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax. 1998;53(10):815-7. PMID: 30267871

    • Early fibrosis concept

---

Related Topics

Prerequisites

• [[Respiratory Physiology]] - V/Q matching, shunt, dead space
• [[Pulmonary Anatomy]] - Alveolar structure, pulmonary circulation
• [[Inflammatory Response]] - Cytokines, complement, neutrophil function

Related Basic Sciences

• [[Surfactant Physiology]] - Composition, function, synthesis
• [[Coagulation Cascade]] - Microthrombosis, fibrin formation
• [[Oxidative Stress]] - ROS generation, antioxidant systems

Clinical Applications

• [[ARDS Clinical Management]] - Ventilator strategies, proning, ECMO
• [[Mechanical Ventilation]] - Modes, settings, monitoring
• [[Sepsis]] - Indirect ARDS aetiology
• [[Pneumonia]] - Direct ARDS aetiology
• [[Pulmonary Hypertension]] - ARDS complication

---

Topic Generated: CICM First Part Basic Science - ARDS Pathology
Lines: 1,987
Citations: 48 PubMed PMIDs
Last Updated: January 2026